Loading clinical trials...
Loading clinical trials...
A Two-Period Crossover Study to Compare the Systemic Exposure to Trans-Capsaicin and Cis-Capsaicin From an Intra-Articular Injection of CNTX-4975-05 (Trans-capsaicin for Injection) and Topical 8% Capsaicin Patch (Qutenza®) in Subjects With Painful Knee Osteoarthritis
Conditions
Interventions
CNTX-4975-05
Qutenza
+1 more
Locations
1
United States
Well Pharma Medical Research, Corp
Miami, Florida, United States
Start Date
June 25, 2018
Primary Completion Date
September 6, 2018
Completion Date
September 6, 2018
Last Updated
November 14, 2018
NCT07351968
NCT06747494
NCT06906939
NCT07224958
NCT06721897
NCT06600958
Lead Sponsor
Centrexion Therapeutics
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions